Time to reconsider CD33 single nucleotide polymorphism in the response to gemtuzumab ozogamicin

Department of Pharmacotherapy and Translational Research, Center for Pharmacogenomics, College of Pharmacy, UF Health Cancer Center, University of Florida, Gainesville
Division of Pediatric Hematology/Oncology, Fred Hutchinson Cancer Research Center, Seattle, Washington
Vol. 106 No. 11 (2021): November, 2021 https://doi.org/10.3324/haematol.2021.279043